| Mon, Nov 9, 2009 | | | Two Stocks with Market Caps Over $250 Million That Sell for Under $10 at Seeking Alpha (Mon 6:23am)
| | | PDL BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online (Mon 6:03am)
| | Sat, Nov 7, 2009 | | | Genmab to cut 130 jobs in Brooklyn Park, sell biotech factory at bizjournals.com (Sat, Nov 7)
| | Fri, Nov 6, 2009 | | | PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disp EDGAR Online (Fri, Nov 6)
| | Thu, Nov 5, 2009 | | | UPDATE - Genmab US plant sale, job cuts to hit year results at Reuters (Thu, Nov 5)
| | Tue, Nov 3, 2009 | | | PDL BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online (Tue, Nov 3)
| | Mon, Nov 2, 2009 | | | PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction PR Newswire (Mon, Nov 2)
| | Wed, Oct 28, 2009 | | | PDL BioPharma Q3 2009 Earnings Call Transcript at Seeking Alpha (Wed, Oct 28)
| | | PDL BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina EDGAR Online (Wed, Oct 28)
| | | PDL BioPharma, Inc. Earnings Call scheduled for 8:30 am ET today CCBN (Wed, Oct 28)
| | | PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction PR Newswire (Wed, Oct 28)
| | | PDL BioPharma Announces Third Quarter 2009 Financial Results PR Newswire (Wed, Oct 28)
| | | Q3 2009 PDL BioPharma, Inc. Earnings Release - Before Market Open CCBN (Wed, Oct 28)
| | Tue, Oct 27, 2009 | | | PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009 PR Newswire (Tue, Oct 27)
| | | PDL BioPharma Reschedules Third Quarter 2009 Financial Results Conference Call for 8:30 a.m. ET on October 28, 2009 PR Newswire (Tue, Oct 27)
| | Thu, Oct 22, 2009 | | | PDL BioPharma to Announce Third Quarter 2009 Financial Results and Hold Conference Call October 28, 2009 PR Newswire (Thu, Oct 22)
| | Wed, Oct 21, 2009 | | | PDL BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online (Wed, Oct 21)
| | Tue, Oct 20, 2009 | | | Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst Wall Street Transcript (Tue, Oct 20)
| | | New Formulation Of Diclofenac Successful In Two Phase III Trials, Approval Will Be Catalyst For Stock According To Industry Expert Wall Street Transcript (Tue, Oct 20)
| | | "Best In Class" Formulation Of Fentanyl Seen As Breakthrough Treatment By Ladenburg Thalmann Analyst Wall Street Transcript (Tue, Oct 20)
| Add PDLI News to My Yahoo!:

| |
|